Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.86 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.86 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.86 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.86 |
| ▸ | NSD2 | O96028 | 1/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.86 |
| ▸ | BID | P55957 | 1/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.86 |
| ▸ | ASPH | Q12797 | 1/20 | 0.86 |
| ▸ | BAD | Q92934 | 1/20 | 0.86 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.86 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.86 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Venetoclax SCHEMBL29801595 | 0.93 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL29353714 | 0.93 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL523816 | 0.93 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL29390802 | 0.93 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL29360081 | 0.93 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL21233545 | 0.92 | BCL2 (0.85) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL19278845 | 0.92 | BCL2 (0.99) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL19278891 | 0.92 | BCL2 (0.98) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL19278892 | 0.92 | BCL2 (0.98) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16038769 | 0.91 | BCL2 (0.96) | BCL2BCL2L1MCL1BCL2L2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285364-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | SERVIER PHARMACEUTICALS LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230074759-A1 | METHODS AND COMPOSITIONS FOR TREATING B-CELL MALIGNANCIES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285364-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | DHODH, DPYD, DLD | BCL2 1647/4885BCL2L1 1551/4885MCL1 275/4885 |
| US-20230074759-A1 | METHODS AND COMPOSITIONS FOR TREATING B-CELL MALIGNANCIES | MALT1, BCL6, BCL3 | BCL2 6/4885BCL2L1 8/4885MCL1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.